RESUMO
AIM: To conduct a meta-analysis of randomised clinical trials (RCTs) in order to evaluate the development of conjunctival hyperaemia after the use of latanoprost versus travoprost and bimatoprost, in patients with ocular hypertension or glaucoma. METHODS: In order to identify the potentially relevant RCTs, a systematic literature retrieval was conducted in Medline, Embase and Cochrane Controlled Trials Register (1995-April 2007) databases The outcome measure was the appearance of conjunctival hyperaemia during the study. Statistical analyses included the calculation of odds ratio (OR) and its respective confidence interval, along with intertrial statistical heterogeneity. Publication bias was evaluated through a funnel plot, and a sensitivity analysis was also performed. RESULTS: In total, 13 RCTs involving 2222 patients with ocular hypertension or glaucoma were included, five comparing latanoprost versus travoprost, seven comparing latanoprost versus bimatoprost and one comparing latanoprost versus travoprost and bimatoprost. The combined results showed that latanoprost produced lower occurrence of conjunctival hyperaemia than both travoprost (OR = 0.51; 95% CI 0.39 to 0.67, p<0.0001) and bimatoprost (OR = 0.32; 95% CI 0.24 to 0.42, p<0.0001). No significant heterogeneity was found between the included RCTs. There was no evidence of publication bias. In the sensitivity analysis performed, none of the clinical trials included in this meta-analysis has an important impact in the global estimation of OR. CONCLUSIONS: According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma.
Assuntos
Anti-Hipertensivos/efeitos adversos , Doenças da Túnica Conjuntiva/induzido quimicamente , Glaucoma/tratamento farmacológico , Hiperemia/induzido quimicamente , Hipertensão Ocular/tratamento farmacológico , Prostaglandinas F Sintéticas/efeitos adversos , Idoso , Amidas/efeitos adversos , Amidas/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Bimatoprost , Cloprostenol/efeitos adversos , Cloprostenol/análogos & derivados , Cloprostenol/uso terapêutico , Doenças da Túnica Conjuntiva/complicações , Feminino , Glaucoma/complicações , Humanos , Hiperemia/complicações , Latanoprosta , Masculino , Pessoa de Meia-Idade , Hipertensão Ocular/complicações , Prostaglandinas F Sintéticas/uso terapêutico , Prostaglandinas Sintéticas/efeitos adversos , Prostaglandinas Sintéticas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , TravoprostRESUMO
We report a patient who developed secondary glaucoma 1 year after phakic posterior chamber intraocular lens implantation.
